[go: up one dir, main page]

WO2007105058A8 - Pyrazole compounds - Google Patents

Pyrazole compounds

Info

Publication number
WO2007105058A8
WO2007105058A8 PCT/IB2007/000561 IB2007000561W WO2007105058A8 WO 2007105058 A8 WO2007105058 A8 WO 2007105058A8 IB 2007000561 W IB2007000561 W IB 2007000561W WO 2007105058 A8 WO2007105058 A8 WO 2007105058A8
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazole compounds
compounds
pyrazole
solvates
synthesis
Prior art date
Application number
PCT/IB2007/000561
Other languages
French (fr)
Other versions
WO2007105058A2 (en
WO2007105058A3 (en
Inventor
Michael John Bennett
Sujin Cho-Schultz
Judith Gail Deal
Stephen Joseph King
Tami Jo Marrone
Cynthia Louise Palmer
Iii William Henry Romines
Eugene Yuanjin Rui
Scott Channing Sutton
Luke Raymond Zehnder
Original Assignee
Pfizer Prod Inc
Michael John Bennett
Sujin Cho-Schultz
Judith Gail Deal
Stephen Joseph King
Tami Jo Marrone
Cynthia Louise Palmer
Iii William Henry Romines
Eugene Yuanjin Rui
Scott Channing Sutton
Luke Raymond Zehnder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Michael John Bennett, Sujin Cho-Schultz, Judith Gail Deal, Stephen Joseph King, Tami Jo Marrone, Cynthia Louise Palmer, Iii William Henry Romines, Eugene Yuanjin Rui, Scott Channing Sutton, Luke Raymond Zehnder filed Critical Pfizer Prod Inc
Priority to EP07705682A priority Critical patent/EP2024353A2/en
Priority to CA002643066A priority patent/CA2643066A1/en
Priority to JP2008558927A priority patent/JP2009530261A/en
Publication of WO2007105058A2 publication Critical patent/WO2007105058A2/en
Publication of WO2007105058A3 publication Critical patent/WO2007105058A3/en
Publication of WO2007105058A8 publication Critical patent/WO2007105058A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention is directed to compounds of Formula (I), and to salts and solvates thereof, their synthesis, and their use as Raf inhibitors.
PCT/IB2007/000561 2006-03-16 2007-03-05 Pyrazole compounds WO2007105058A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07705682A EP2024353A2 (en) 2006-03-16 2007-03-05 Pyrazole compounds
CA002643066A CA2643066A1 (en) 2006-03-16 2007-03-05 Pyrazole compounds
JP2008558927A JP2009530261A (en) 2006-03-16 2007-03-05 Pyrazole compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US78278606P 2006-03-16 2006-03-16
US60/782,786 2006-03-16
US88656107P 2007-01-25 2007-01-25
US60/886,561 2007-01-25

Publications (3)

Publication Number Publication Date
WO2007105058A2 WO2007105058A2 (en) 2007-09-20
WO2007105058A3 WO2007105058A3 (en) 2007-12-21
WO2007105058A8 true WO2007105058A8 (en) 2008-10-16

Family

ID=38235169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/000561 WO2007105058A2 (en) 2006-03-16 2007-03-05 Pyrazole compounds

Country Status (4)

Country Link
EP (1) EP2024353A2 (en)
JP (1) JP2009530261A (en)
CA (1) CA2643066A1 (en)
WO (1) WO2007105058A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
US8653262B2 (en) * 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
EP2183243A2 (en) 2007-08-01 2010-05-12 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
BRPI0820544A2 (en) 2007-11-16 2015-06-16 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
WO2009070547A1 (en) * 2007-11-28 2009-06-04 Tragara Pharmaceuticals, Inc. Cancer treatment using cox-2 inhibitor and antimetabolite combinations
SI2324008T1 (en) * 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarylpyrazoles as protein kinase inhibitors
US20120053164A1 (en) 2008-12-19 2012-03-01 Boehringer Ingelheim International Gmbh Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
JP5490137B2 (en) * 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Bicyclic pyrazoles as protein kinase inhibitors
KR101111247B1 (en) * 2009-07-17 2012-06-12 한국과학기술연구원 Pyrazole compounds for Ros kinase inhibitors
AR077975A1 (en) 2009-08-28 2011-10-05 Irm Llc PIRAZOL PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
KR101123071B1 (en) * 2009-10-23 2012-03-05 한국과학기술연구원 Novel imidazole derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for the prevention and treatment of melanoma containing the same as an active ingredient
JP5632014B2 (en) 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel CCR2 receptor antagonists and uses thereof
KR20120133377A (en) * 2010-01-27 2012-12-10 네르비아노 메디칼 사이언시스 에스.알.엘. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
JP2013526507A (en) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング NOVEL CCR2 RECEPTOR ANTAGONIST, PROCESS FOR PRODUCING THE SAME AND USE THEREOF AS DRUG
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
JP5647339B2 (en) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CCR2 antagonists and uses thereof
JP5636094B2 (en) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング CCR2 receptor antagonist
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JP5938038B2 (en) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ Derivatives of pyrazolophenyl-benzenesulfonamide compounds and their use as antitumor agents
WO2012074067A1 (en) * 2010-12-01 2012-06-07 日産化学工業株式会社 Pyrazole compound having therapeutic effect on multiple myeloma
BR112013021941B1 (en) 2011-04-18 2022-11-16 Eisai R & D Management Co., Ltd THERAPEUTIC AGENT FOR TUMOR
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
MX354725B (en) 2011-11-11 2018-03-16 Novartis Ag Method of treating a proliferative disease.
DK2782557T3 (en) 2011-11-23 2018-12-10 Array Biopharma Inc PHARMACEUTICAL FORMULATIONS
MX2016008362A (en) 2013-12-23 2016-09-08 Novartis Ag Pharmaceutical combinations.
PT3317270T (en) 2015-07-02 2020-08-24 Centrexion Therapeutics Corp (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
US11472791B2 (en) 2019-03-05 2022-10-18 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
PE20221010A1 (en) 2019-08-14 2022-06-15 Incyte Corp IMIDAZOLIL PYRIMIDINILAMINE COMPOUNDS AS CDK2 INHIBITORS
JOP20220087A1 (en) 2019-10-11 2023-01-30 Incyte Corp Bicyclic amines as inhibitors of CDK2
WO2021120890A1 (en) 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
MX2023005078A (en) * 2020-10-30 2023-05-16 Novartis Ag New crystalline forms of a kras g12c inhibitor compound.
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID22982A (en) * 1997-05-22 1999-12-23 Searle & Co SUBSTITUTED PIRAZOLS AS KINASE INHIBITORS p38
AU7922100A (en) * 1999-10-25 2001-05-08 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles as the active agents and use of said compositions as plant protection agents with a fungicidal action
US7247734B2 (en) * 2001-12-21 2007-07-24 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
AR040442A1 (en) * 2002-06-05 2005-04-06 Pharmacia Corp DERIVATIVES OF PIRAZOL AS INHIBITORS OF QUINASA P38
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds
UA86283C2 (en) * 2005-01-07 2009-04-10 Пфайзер Продактс Инк. Heteroaromatic quinoline compounds and use thereof as pde10 inhibitors

Also Published As

Publication number Publication date
WO2007105058A2 (en) 2007-09-20
JP2009530261A (en) 2009-08-27
WO2007105058A3 (en) 2007-12-21
CA2643066A1 (en) 2007-09-20
EP2024353A2 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
WO2007105058A8 (en) Pyrazole compounds
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
MX2009003834A (en) Pyrrolydine derivatives as iap inhibitors.
MY148634A (en) Pyridazinone derivatives
SG171593A1 (en) Inhibitors of c-fms kinase
GEP20115306B (en)
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
WO2008055068A3 (en) Inhibitors of histone deacetylase
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2006133147A3 (en) Organic compounds
WO2009156462A3 (en) Organic compounds
WO2007085895A3 (en) Fap inhibitors
WO2007019191A3 (en) Thiazolopyrimidine kinase inhibitors
WO2008109181A3 (en) Metalloprotease inhibitors containing a heterocyclic moiety
WO2006052568A3 (en) Tgf-beta inhibitors
MX2012001617A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives.
EA201200891A1 (en) DERIVATIVES 3,4,4A, 10D-TETRAGIDRO-1H-TIOPIRANO [4,3-C] IZOHINOLINA
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
WO2009003672A3 (en) Novel microbiocides
TN2009000536A1 (en) Novel herbicides
WO2009010479A3 (en) Heterocyclic methylene piperidine derivatives and their use
WO2008019030A8 (en) Modified azole compounds as antiinfective agents
MY154498A (en) Pyrazolone derivatives as pde4 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2643066

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008558927

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007705682

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07705682

Country of ref document: EP

Kind code of ref document: A2